MCID: ADN021
MIFTS: 68

Adenomatous Polyposis Coli malady

Categories: Genetic diseases, Rare diseases, Eye diseases, Gastrointestinal diseases, Skin diseases, Fetal diseases, Cancer diseases, Neuronal diseases, Bone diseases

Aliases & Classifications for Adenomatous Polyposis Coli

About this section
Sources:
49OMIM, 11diseasecard, 65UMLS, 24GTR, 45NIH Rare Diseases, 22GeneTests, 51Orphanet, 67UniProtKB/Swiss-Prot, 47Novoseek, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Adenomatous Polyposis Coli:

Name: Adenomatous Polyposis Coli 49 11 65
Gardner Syndrome 49 45 22 51 65
Brain Tumor-Polyposis Syndrome 2 49 24 65
Gardners Syndrome 47 24
Polyposis Coli and Multiple Hard and Soft Tissue Tumors 45
 
Intestinal Polyposis, Osteomas, Sebaceous Cysts 45
Familial Adenomatous Polyposis 1 24
Familial Adenomatous Polyposis 67
Gardner's Syndrome 45
Fap 67

Characteristics:

HPO:

61
adenomatous polyposis coli:
Onset and clinical course: variable expressivity
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 175100
Orphanet51 79665
ICD10 via Orphanet28 D12.6
MESH via Orphanet37 D005736
UMLS via Orphanet66 C0017097
UMLS65 C2673218, C0017097

Summaries for Adenomatous Polyposis Coli

About this section
NIH Rare Diseases:45 Gardner syndrome is a form of familial adenomatous polyposis (fap) that is characterized by multiple colorectal polyps and various types of tumors, both benign (noncancerous) and malignant (cancerous). people affected by gardner syndrome have a high risk of developing colorectal cancer at an early age. they are also at an increased risk of developing other fap-related cancers, such as those of the small bowel, stomach, pancreas, thyroid, central nervous system, liver, bile ducts, and/or adrenal gland. other signs and symptoms of gardner syndrome include dental abnormalities; osteomas (benign bone growths); various skin abnormalities such as epidermoid cysts, fibromas (a benign tumor of the connective tissue), and lipomas; and desmoid tumors. it is caused by changes (mutations) in the apc gene and inherited in an autosomal dominant manner. although there is no cure for gardner syndrome, management options are available to reduce the risk of cancer. these may include high risk screening, prophylactic surgeries and/or certain types of medications. last updated: 1/14/2015

MalaCards based summary: Adenomatous Polyposis Coli, also known as gardner syndrome, is related to colorectal cancer and familial adenomatous polyposis, and has symptoms including intestinal polyposis, adenomatous colonic polyposis and neoplasm of the colon. An important gene associated with Adenomatous Polyposis Coli is APC (Adenomatous Polyposis Coli), and among its related pathways are C-MYC pathway and RHO GTPases activate IQGAPs. The drug celecoxib has been mentioned in the context of this disorder. Affiliated tissues include colon, thyroid and brain, and related mouse phenotypes are liver/biliary system and tumorigenesis.

UniProtKB/Swiss-Prot:67 Familial adenomatous polyposis: A cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.

OMIM:49 Familial adenomatous polyposis-1 is an autosomal dominant disorder characterized by predisposition to cancer. Affected... (175100) more...

Wikipedia:68 This article refers to the tumor suppressor APC, in which mutations lead to colon cancer. For the... more...

Related Diseases for Adenomatous Polyposis Coli

About this section

Diseases related to Adenomatous Polyposis Coli via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 78)
idRelated DiseaseScoreTop Affiliating Genes
1colorectal cancer27.1APC, AXIN1, AXIN2, CTNNB1, GLUL, GSK3B
2familial adenomatous polyposis12.0
3samson gardner syndrome11.9
4attenuated familial adenomatous polyposis11.6
5mismatch repair cancer syndrome11.3
6mutyh-associated polyposis11.3
7adenoma10.5
8fibrous meningioma10.5APC, CTNNB1
9myh9-related disorders10.4APC, MUTYH
10ehlers-danlos syndrome, type viic10.4APC, GLUL
11atypical mole syndrome10.4APC, MUTYH
12breast cancer10.4
13familial congenital fourth cranial nerve palsy10.4APC, MUTYH
14biliary tract neoplasm10.3APC, CTNNB1, MUTYH
15hepatocellular adenoma10.3
16ulnar neuropathy10.3APC, CTNNB1, MUTYH
17organ system benign neoplasm10.3APC, CTNNB1, MUTYH
18multiple skull base meningioma10.3AXIN1, AXIN2, CTNNB1
19hepatocellular carcinoma10.3
20colorectal adenoma10.3
21oral squamous cell carcinoma10.3
22thyroiditis10.3
23neuronitis10.3
24common variable immunodeficiency10.3APC, CTNNB1, MUTYH
25tenosynovitis of foot and ankle10.2APC, CTNNB1, MUTYH
26lung cancer10.2
27desmoid tumor10.2
28hilar lung neoplasm10.2AXIN1, CTNNB1
29retinoblastoma10.1
30ulcerative colitis10.1
31ameloblastoma10.1
32colitis10.1
33iron metabolism disease10.1APC, CTNNB1
34gastric cancer, somatic10.1APC, GLUL, MUTYH
35gingival recession10.0APC, CTNNB1, MUTYH
36sost-related sclerosing bone dysplasia10.0CTNNB1, WNT1
37non-invasive bladder urothelial carcinoma10.0APC, AXIN2, CTNNB1, MUTYH
38schizophrenia10.0
39medulloblastoma10.0
40parathyroid carcinoma10.0
41adult t-cell leukemia10.0
42gastric cancer10.0
43hepatitis10.0
44hepatitis b10.0
45leukemia10.0
46colorectal adenocarcinoma10.0
47autism spectrum disorder10.0
48lymphoma10.0
49stomach cancer10.0
50fourth cranial nerve palsy10.0

Graphical network of the top 20 diseases related to Adenomatous Polyposis Coli:



Diseases related to adenomatous polyposis coli

Symptoms for Adenomatous Polyposis Coli

About this section

Symptoms by clinical synopsis from OMIM:

175100

Clinical features from OMIM:

175100

HPO human phenotypes related to Adenomatous Polyposis Coli:

(show all 32)
id Description Frequency HPO Source Accession
1 intestinal polyposis hallmark (90%) HP:0200008
2 adenomatous colonic polyposis hallmark (90%) HP:0005227
3 neoplasm of the colon typical (50%) HP:0100273
4 duodenal polyposis typical (50%) HP:0004783
5 multiple gastric polyps frequent (33%) HP:0004394
6 colon cancer frequent (33%) HP:0003003
7 adrenocortical adenoma 13% HP:0008256
8 desmoid tumors 10% HP:0100245
9 epidermoid cyst occasional (7.5%) HP:0200040
10 odontogenic neoplasm occasional (7.5%) HP:0100612
11 osteoma occasional (7.5%) HP:0100246
12 sarcoma occasional (7.5%) HP:0100242
13 increased number of teeth occasional (7.5%) HP:0011069
14 fibroadenoma of the breast occasional (7.5%) HP:0010619
15 congenital hypertrophy of retinal pigment epithelium occasional (7.5%) HP:0007649
16 irregular hyperpigmentation occasional (7.5%) HP:0007400
17 neoplasm of the nervous system occasional (7.5%) HP:0004375
18 multiple lipomas occasional (7.5%) HP:0001012
19 unerupted tooth occasional (7.5%) HP:0000706
20 delayed eruption of teeth occasional (7.5%) HP:0000684
21 carious teeth occasional (7.5%) HP:0000670
22 duodenal adenocarcinoma 4% HP:0006771
23 hepatoblastoma 1.6% HP:0002884
24 papillary thyroid carcinoma very rare (1%) HP:0002895
25 medulloblastoma very rare (1%) HP:0002885
26 odontoma HP:0011068
27 keloids HP:0010562
28 astrocytoma HP:0009592
29 adrenocortical carcinoma HP:0006744
30 small intestine carcinoid HP:0006722
31 multiple lipomas HP:0001012
32 hyperpigmentation of the skin HP:0000953

UMLS symptoms related to Adenomatous Polyposis Coli:


diarrhea, abdominal pain

Drugs & Therapeutics for Adenomatous Polyposis Coli

About this section

Drugs for Adenomatous Polyposis Coli (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 66)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Celecoxibapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1419169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
2
ErythromycinapprovedPhase 492114-07-812560
Synonyms:
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
,10-dione
114-07-8
3''-O-demethylerythromycin
374700-25-1
45673_FLUKA
45674_FLUKA
79235-06-6
82343-12-2
A/T/S
AC-12744
AC1L1FIQ
AC1L1QK7
AC1L1ZUR
AC1O8PVA
AC1Q2UA1
AC1Q6O1S
AI3-50138
AR-1A4414
AR-1H0723
Abboticin
Abomacetin
Acneryne
Acnesol
Ak-Mycin
Ak-mycin
Akne Cordes Losung
Akne-Mycin
Akne-mycin
Akne-mycin (TN)
Aknederm Ery Gel
Aknemycin
Aknin
AustriaS
BB_NC-1332
BIDD:GT0017
BPBio1_000312
BSPBio_000282
BSPBio_002480
Benzamycin
Benzamycin Pak
Bristamycin
C-Solve-2
C01912
C37H67NO13
CCRIS 9078
CHEBI:42355
CHEMBL532
CID12560
CID3255
CID6713919
CID8233
D00140
DB00199
Del-Mycin
Derimer
Deripil
DivK1c_000294
DivK1c_000397
DivK1c_000702
Dotycin
Dumotrycin
E- mycin, Erycin, Robimysin
E-Base
E-Base (base)
E-Glades
E-Mycin
E-Mycin (base)
E-Solve 2
E.e.s
E.e.s.
E0751
E0774_SIAL
E5389_SIGMA
E6376_SIAL
E7904_SIGMA
EINECS 204-040-1
EM
EMU
ERY
ERYC
ERYC (base)
ERYTHROMYCIN STEARATE
ETS
Emgel
Emu-V
Emu-Ve
Emuvin
Emycin
Endoeritrin
Erecin
Erimycin-T
Erisone
Eritomicina
Eritrocina
Eritromicina
Eritromicina [INN-Spanish]
Ermycin
Eros
Ery
Ery-B
Ery-Diolan
Ery-Sol
Ery-Tab
Ery-Tab (base)
Ery-maxin
Ery-ped
Ery-tab
Eryacne
Eryacnen
Erybid
Eryc
Eryc (TN)
Eryc 125
Eryc Sprinkles
Eryc-125
Eryc-250
Erycen
Erycette
Erycin
Erycinum
Eryderm
Erydermer
Erygel
Erygel (TN)
Eryhexal
Erymax
Erymed
Erypar
Erysafe
Erytab
Erythra-Derm
Erythra-derm
Erythro
Erythro-Statin
Erythro-Teva
Erythrocin
Erythrocin Stearate
Erythroderm
Erythrogran
Erythroguent
Erythromast 36
Erythromid
 
Erythromycin
Erythromycin & VRC3375
Erythromycin (JP15/USP/INN)
Erythromycin A
Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279
Erythromycin B
Erythromycin Base
Erythromycin Base Base
Erythromycin Base Filmtab
Erythromycin C
Erythromycin Lactate
Erythromycin Ointment
Erythromycin Stearate
Erythromycin [INN:BAN:JAN]
Erythromycin base
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin glucoheptonate
Erythromycin intravenous
Erythromycin lactobionate
Erythromycin oxime
Erythromycin sodium lauryl sulfate
Erythromycin, compd. with monododecyl sulfate, sodium salt
Erythromycine
Erythromycine [INN-French]
Erythromycinum
Erythromycinum [INN-Latin]
Erytop
Erytrociclin
Ethril 250
HMS1568O04
HMS1920M04
HMS2091D05
HMS500O16
HSDB 3074
I06-0245
IDI1_000294
IDI1_000397
IDI1_000702
Ilocaps
Ilosone
Ilosone (estolate)
Iloticina
Ilotycin
Ilotycin Gluceptate
Ilotycin T.S
Ilotycin T.S.
Inderm
Inderm Gel
IndermRetcin
KBio1_000294
KBio1_000397
KBio1_000702
KBio2_000555
KBio2_001139
KBio2_003123
KBio2_003707
KBio2_005691
KBio2_006275
KBioGR_001175
KBioSS_000555
KBioSS_001139
KST-1A8261
Kesso-Mycin
LMPK04000006
LS-187077
LS-64648
Latotryd
Lederpax
MLS001066618
Mephamycin
Mercina
MolPort-000-772-161
MolPort-002-507-378
MolPort-003-933-429
N-Methylerythromycin A
NCGC00179619-01
NCI-C55674
NINDS_000294
NINDS_000397
NINDS_000702
NSC 55929
NSC55929
Oftalmolosa Cusi Eritromicina
Oftamolets
PCE Dispertab (base)
Paediathrocin
Pantoderm
Pantodrin
Pantomicina
Pce
Pce (TN)
Pfizer-e
Pharyngocin
Prestwick0_000151
Prestwick1_000151
Prestwick2_000151
Prestwick3_000151
Prestwick_205
Primacine
Propiocine
Proterytrin
R-P Mycin
Retcin
Robimycin
Romycin
SBB057401
SMP1_000119
SMR000544946
SPBio_000778
SPBio_001226
SPBio_002221
SPECTRUM1500280
STK249736
Sans-acne
Sansac
Serp-AFD
Skid Gel E
Spectrum2_000759
Spectrum2_001263
Spectrum4_000538
Spectrum5_001596
Spectrum_000115
Spectrum_000659
Staticin
Staticin (TN)
Stiemicyn
Stiemycin
Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin
T-Stat
T-stat (TN)
Taimoxin-F
Theramycin Z
Tiloryth
Tiprocin
Torlamicina
UNII-63937KV33D
Udima Ery Gel
Wemid
Wyamycin S
adecane-2,10-dione (non-preferred name)
bmse000664
erythro
erythromycin
nchembio.285-comp13
3Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 2, Phase 3, Phase 13549
4Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 18478
5Cyclooxygenase 2 InhibitorsPhase 4, Phase 2, Phase 3, Phase 1538
6Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 118510
7Analgesics, Non-NarcoticPhase 4, Phase 2, Phase 3, Phase 15184
8Cyclooxygenase InhibitorsPhase 4, Phase 2, Phase 3, Phase 12225
9Antirheumatic AgentsPhase 4, Phase 2, Phase 3, Phase 18496
10AnalgesicsPhase 4, Phase 2, Phase 3, Phase 19358
11Gastrointestinal AgentsPhase 4, Phase 2, Phase 36401
12Erythromycin EstolatePhase 492
13Anti-Bacterial AgentsPhase 4, Phase 1, Phase 29140
14Anti-Infective AgentsPhase 4, Phase 3, Phase 1, Phase 217220
15Erythromycin stearatePhase 492
16Erythromycin EthylsuccinatePhase 492
17
Ursodeoxycholic acidapproved, investigationalPhase 2, Phase 378128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
ISO-URSODEOXYCHOLIC ACID
 
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol Tablets, 250 mg
Ursodiol Tablets, 500 mg
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
18
LoperamideapprovedPhase 311253179-11-63955
Synonyms:
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6
AB00053697
AC1L1H38
AKOS000573892
Apo-Loperamide
BAS 01889668
BPBio1_000274
BRD-K61250553-001-02-9
BRD-K61250553-003-05-8
BRN 1558273
BSPBio_000248
BSPBio_001381
BSPBio_002769
Bio1_000082
Bio1_000571
Bio1_001060
Bio2_000101
Bio2_000581
C07080
C29H33ClN2O2
CAS-34552-83-5
CBiol_001796
CHEBI:162259
CHEBI:6532
CHEMBL841
CID3955
D08144
DB00836
Diamide (TN)
Diarr-Eze
DivK1c_000215
EINECS 258-416-5
HMS1791F03
HMS1989F03
HMS2089C13
IDI1_000215
IDI1_033851
Imodium A-D
Imodium A-D Caplets
Ioperamide
KBio1_000215
KBio2_000101
KBio2_000854
KBio2_002669
KBio2_003422
KBio2_005237
KBio2_005990
KBio3_000201
KBio3_000202
 
KBio3_001989
KBioGR_000101
KBioGR_001685
KBioSS_000101
KBioSS_000854
Kaopectate II
L000709
LS-114352
Lopac-L-4762
Lopac0_000708
Loperacap
Loperamid
Loperamida
Loperamida [INN-Spanish]
Loperamide
Loperamide (INN)
Loperamide Hydrochloride
Loperamide Monohydrochloride
Loperamide [INN:BAN]
Loperamide hydrochloride
Loperamidum
Loperamidum [INN-Latin]
Lopéramide
Maalox Anti-Diarrheal
MolPort-001-969-016
NCGC00015608-01
NCGC00015608-08
NCGC00016828-01
NCGC00024818-01
NCGC00024818-02
NCGC00024818-03
NCGC00024818-04
NCGC00024818-05
NINDS_000215
Nu-Loperamide
Oprea1_109220
PMS-Loperamide
Pepto Diarrhea Control
Prestwick0_000144
Prestwick1_000144
Prestwick2_000144
Prestwick3_000144
R-18553
Rho-Loperamide
SPBio_001816
SPBio_002187
ST095179
Spectrum2_001738
Spectrum3_001015
Spectrum4_001143
Spectrum5_001374
Spectrum_000374
Tocris-0840
UNII-6X9OC3H4II
loperamide
nchembio.559-comp8
nchembio.79-comp7
19
SulindacapprovedPhase 3, Phase 23538194-50-25352, 1548887
Synonyms:
(E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((P-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid
2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
32004-68-5
38194-50-2
5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
53933-60-1
6301-55-9
9000-14-0
AB00513800
AC-4550
AC1L1K5T
AC1LU7GU
AC1LU7GY
AC1Q6YHK
AKOS004119989
AR-1A9609
Aclin
Aflodac
Alphapharm Brand of Sulindac
Apo Sulin
Apo-Sulin
Apotex Brand of Sulindac
Arthrobid
Arthrocine
BB_SC-1128
BPBio1_000315
BRD-A03427350-001-01-3
BRD-A13946108-001-04-9
BRN 2951842
BSPBio_000285
BSPBio_002890
C01531
C20H17FO3S
CAS-38194-50-2
CCRIS 3305
CHEBI:9352
CHEMBL1376
CID1548885
CID1548887
CID5352
CPD000326718
Cahill May Roberts Brand of Sulindac
Chemia Brand of Sulindac
Chibret
Clinoril
Clinoril (TN)
Copal
Copal resin
Copal rosin varnish
Copals
D00120
D013467
DB00605
DivK1c_000601
EINECS 232-527-9
EINECS 250-893-8
EINECS 253-819-2
EINECS 258-873-0
EU-0101070
Gum copal
HMS1568O07
HMS1921C11
HMS2089J04
HMS2092K15
HMS501O03
I06-0523
IDI1_000601
KBio1_000601
KBio2_001506
KBio2_002320
KBio2_004074
KBio2_004888
KBio2_006642
KBio2_007456
KBio3_002110
KBio3_002800
KBioGR_001571
 
KBioGR_002320
KBioSS_001506
KBioSS_002322
KST-1B6530
Kenalin
Kendrick Brand of Sulindac
Klinoril
LS-81610
Lopac-S-8139
Lopac0_001070
MK 231
MK-231
MK231
MLS001056554
MLS001304027
MLS002207124
Merck Brand of Sulindac
Merck Sharp & Dohme Brand of Sulindac
Mobilin
MolPort-002-507-760
MolPort-003-666-287
NCGC00015970-01
NCGC00015970-02
NCGC00015970-03
NCGC00015970-08
NCGC00025268-01
NCGC00025268-02
NCGC00025268-03
NCGC00094349-01
NCGC00094349-02
NINDS_000601
Novo Sundac
Novo-Sundac
Novopharm Brand of Sulindac
Nu Pharm Brand of Sulindac
Nu Sulindac
Nu-Pharm Brand of Sulindac
Nu-Sulindac
Prestwick0_000073
Prestwick1_000073
Prestwick2_000073
Prestwick3_000073
Prestwick_456
Resin copal
S 8139
S2007_Selleck
S4429_SIAL
S8139_SIAL
S8139_SIGMA
SAM002554933
SBB058181
SMR000043852
SMR000326718
SPBio_001451
SPBio_002206
SPECTRUM1500556
STK802068
Spectrum2_001326
Spectrum3_001365
Spectrum4_000876
Spectrum5_001024
Spectrum_001026
Sulindac
Sulindac (JAN/USP/INN)
Sulindac [USAN:BAN:INN:JAN]
Sulindac sulfoxide
Sulindaco
Sulindaco [INN-Spanish]
Sulindacum
Sulindacum [INN-Latin]
Sulindal
Tocris-1707
UNII-184SNS8VUH
UNII-M5221THD3M
UNM-0000306136
Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid
[(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid
cMAP_000021
cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((P-methylsulfinyl)benzylidene)indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid
sulindac
{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid
20
DolutegravirapprovedPhase 31231051375-16-6
Synonyms:
 
Dolutegravir Sodium
Tivicay
21
Ornithineapproved, nutraceuticalPhase 3, Phase 26370-26-86262
Synonyms:
(+)-S-Ornithine
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-2,5-diaminovaleric acid
(S)-Ornithine
(S)-a,D-Diaminovalerate
 
(S)-a,D-Diaminovaleric acid
(S)-alpha,delta-Diaminovaleric acid
(S)-ornithine
(S)-α,δ-diaminovaleric acid
5-Amino-L-Norvaline
L-(-)-Ornithine
L-Ornithine
22AntidiarrhealsPhase 3112
23Contraceptives, OralPhase 2, Phase 33734
24
EflornithinePhase 3, Phase 23370052-12-93009
Synonyms:
.alpha.-DFMO HCl
2,5-diamino-2-(difluoromethyl)pentanoic acid
2,5-diamino-2-(difluoromethyl)pentanoic acid hydrate hydrochloride
2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride
2-(Difluoromethyl)-DL-ornithine
2-(Difluoromethyl)-DL-ornithine HCl
2-(Difluoromethyl)-DL-ornithine hydrochloride
2-(Difluoromethyl)-DL-ornithine monohydrochloride
2-(Difluoromethyl)-DL-ornithine monohydrochloride, monohydrate
2-(Difluoromethyl)-DL-ornithine monohydrochloride.monohydrate
2-(Difluoromethyl)ornithine
2-(Difluoromethyl)ornithine hydrochloride hydrate
67037-37-0
68278-23-9
70050-56-5
70052-12-9
70052-12-9 (Parent)
96020-91-6
96020-91-6 (mono-hydrochloride, monohydrate)
AC-388
AC-5497
AC1L1EYW
AC1L1M41
AC1L9B1G
BMS 203522
BRN 2250529
C07997
C6H12F2N2O2.HCl.H2O
CCRIS 3295
CCRIS 3718
CCRIS 5805
CHEBI:41948
CHEMBL1201037
CHEMBL536971
CID3009
CID441361
CID57004
CPP-1X
D,L-alpha-Difluoromethylornithine
D,L-alpha-Difluoromethylornithine hydrochloride
D00829
D07883
D193_SIGMA
DFMO (growth regulator)
DFMO HCl
DFMO hydrochloride
DFMO hydrochloride hydrate
DL-.alpha.-Difluoromethylornithine
DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride
DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate
DL-alpha-(Difluoromethyl)ornithine
DL-alpha-Difluoromethylornithine
DL-alpha-Difluoromethylornithine hydrochloride
DL-alpha-Difluoromethylornithine hydrochloride hydrate
 
DL-alpha-Difluoromethylornithine, Hydrochloride
Difluoromethylornithine
Difluromethylornithine
EFLORNITHINE
EFLORNITHINE HYDROCHLORIDE
EINECS 269-532-0
EU-0100429
Eflornithine (INN)
Eflornithine HCl
Eflornithine [INN:BAN]
Eflornithine hydrochloride (USAN)
Eflornithine hydrochloride [USAN]
Eflornithine hydrochloride hydrate
Eflornithine hydrochloride monohydrate
Eflornithinum
Eflornithinum [Latin]
Eflornitina
Eflornitina [Spanish]
FT-0082608
FT-0082826
HSCI1_000267
I06-0316
I06-0530
LS-178282
LS-185084
LS-7332
LS-98405
Lopac0_000429
MDL 71,782 A
MDL 71782
MDL-71782A
MLS000069341
MLS001332583
MolPort-003-940-991
N-Difluoromethylornithine
NCGC00015316-03
NCGC00093850-01
NCGC00162152-01
NSC270295
NSC337250
Ornidyl
Ornidyl (TN)
Ornithine, 2-(difluoromethyl)-, monohydrochloride
RMI 71782
RMI-71782
SBB066102
SMR000058442
UNII-4NH22NDW9H
UNII-ZQN1G5V6SR
Vaniqa
alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid
alpha-(Difluoromethyl)-DL-ornithine
alpha-Difluoromethylornithine
alpha-Difluoromethylornithine hydrochloride
dfmo
25Antiparasitic AgentsPhase 3, Phase 21854
26Antiprotozoal AgentsPhase 3, Phase 21730
27Integrase InhibitorsPhase 3370
28HIV Integrase InhibitorsPhase 3343
29Antiviral AgentsPhase 38071
30Anti-Retroviral AgentsPhase 32794
31ColaNutraceuticalPhase 2, Phase 3, Phase 11768
32Omega 3 Fatty AcidNutraceuticalPhase 2, Phase 3912
33
Miconazoleapproved, investigationalPhase 1, Phase 2302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
34
Sirolimusapproved, investigationalPhase 1, Phase 2179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
35
EverolimusapprovedPhase 1, Phase 21797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
36
MetforminapprovedPhase 21645657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
37
Inulinapproved, nutraceuticalPhase 2959005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
38
Vitamin Aapproved, nutraceuticalPhase 241311103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(2e,4e,6e,8e)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Chocola a
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A palmitate
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin a
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
39Antibiotics, AntitubercularPhase 1, Phase 25971
40Immunosuppressive AgentsPhase 1, Phase 210422
41Hypoglycemic AgentsPhase 24503
42Immunologic FactorsPhase 1, Phase 218483
43Antifungal AgentsPhase 1, Phase 23015
44
CurcuminPhase 2124458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
45Retinol palmitatePhase 2413
46Protein Kinase InhibitorsPhase 23162
47
Erlotinib HydrochloridePhase 2781183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
48Turmeric extractPhase 257
49Soy BeanNutraceuticalPhase 2455
50TurmericNutraceuticalPhase 264

Interventional clinical trials:

(show top 50)    (show all 70)
idNameStatusNCT IDPhase
1Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous PolyposisRecruitingNCT02175914Phase 4
2Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted VersionNot yet recruitingNCT02354560Phase 4
3A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)TerminatedNCT00140894Phase 4
4Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control PatientsTerminatedNCT00151476Phase 4
5Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPACompletedNCT00510692Phase 2, Phase 3
6Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous PolyposisCompletedNCT00808743Phase 2, Phase 3
7Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove PolypsCompletedNCT00005094Phase 3
8Clinical Approaches to Ileal Pouch DysfunctionCompletedNCT00293553Phase 3
9Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep ApneaCompletedNCT01186926Phase 2, Phase 3
10Use of Post Operative Loperamide in Colorectal Patients After Diverting IleostomiesRecruitingNCT02263365Phase 3
11Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3RecruitingNCT02300558Phase 3
12Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) PatientsActive, not recruitingNCT00134758Phase 2, Phase 3
13Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)Active, not recruitingNCT01483144Phase 3
14Compassionate Use of Ibalizumab for the Treatment of HIV InfectionAvailableNCT02028819Phase 3
15Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)TerminatedNCT00585312Phase 3
16Coxib-inhibition of Duodenal Polyp Growth in FAPTerminatedNCT00844727Phase 2, Phase 3
17A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)WithdrawnNCT01245816Phase 3
18Exisulind in Preventing Polyps in Patients With Familial Adenomatous PolyposisWithdrawnNCT00026468Phase 2, Phase 3
19Effects of Raw Versus Other Milk Sources on Lactose DigestionCompletedNCT01129791Phase 2
20Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous PolyposisRecruitingNCT00319007Phase 2
21The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled StudyRecruitingNCT01725490Phase 2
22A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type FibromatosisRecruitingNCT01265030Phase 1, Phase 2
23Treatment for Presumed Ocular HistoplasmosisRecruitingNCT01790893Phase 1, Phase 2
24A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsActive, not recruitingNCT01187901Phase 2
25Curcumin in Treating Patients With Familial Adenomatous PolyposisActive, not recruitingNCT00641147Phase 2
26Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal CancersActive, not recruitingNCT00503035Phase 2
27Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous PolyposisTerminatedNCT00033371Phase 2
28Outpatient Neutropenic Diet StudyTerminatedNCT00947648Phase 2
29Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis PatientsWithdrawnNCT00248053Phase 2
30Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CWCompletedNCT02113202Phase 1
31Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)CompletedNCT00770991Phase 1
32Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous PolyposisCompletedNCT00685568Phase 1
33A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy VolunteersCompletedNCT00813241Phase 1
34Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet ActionCompletedNCT02060396Phase 1
35Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?CompletedNCT01173250
36A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner SyndromeCompletedNCT01286662
37Single Incision Laparoscopic Surgery in Treating Patients With Colorectal DiseaseCompletedNCT01656746
38Dual Focus NBI and pCLE in FAP Related Duodenal AdenomaCompletedNCT02162173
39Genetic Analysis of Hereditary Prostate CancerCompletedNCT00001469
40Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective StudyCompletedNCT01764503
41Oligogenic Determinism of Colorectal CancerCompletedNCT01057953
42Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance ProgramRecruitingNCT02747862
43Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis PatientsRecruitingNCT01604564
44Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)RecruitingNCT02656134
45Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)RecruitingNCT00927485
46Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer SyndromesRecruitingNCT02198092
47Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard EndoscopyRecruitingNCT00253812
4818F-FES PET/CT in Imaging Patients With Desmoid TumorsRecruitingNCT02374931
49Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals.RecruitingNCT02012699
50French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and HyperplRecruitingNCT01987518

Search NIH Clinical Center for Adenomatous Polyposis Coli

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Adenomatous Polyposis Coli

About this section

Genetic tests related to Adenomatous Polyposis Coli:

id Genetic test Affiliating Genes
1 Gardner Syndrome22

Anatomical Context for Adenomatous Polyposis Coli

About this section

MalaCards organs/tissues related to Adenomatous Polyposis Coli:

33
Colon, Thyroid, Brain, Skin, Bone, Liver, Pancreas

Animal Models for Adenomatous Polyposis Coli or affiliated genes

About this section

MGI Mouse Phenotypes related to Adenomatous Polyposis Coli:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.7APC, CTNNB1, FEN1, GLUL, GSK3B, TCF7L2
2MP:00020068.3APC, CTNNB1, FEN1, IQGAP1, MUTYH, TCF7L2
3MP:00053817.9APC, AXIN1, CTNNB1, FEN1, GSK3B, IQGAP1
4MP:00053807.5AMER1, APC, AXIN1, AXIN2, CTNNB1, FEN1
5MP:00053827.4AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
6MP:00053907.4AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
7MP:00053786.8AMER1, APC, APC2, AXIN1, AXIN2, CTNNB1
8MP:00053846.4AMER1, APC, APC2, AXIN1, AXIN2, CTNNB1
9MP:00036316.3APC, APC2, AXIN1, AXIN2, CTNNB1, FEN1
10MP:00107685.5AMER1, APC, AXIN1, AXIN2, CTNNB1, FEN1

Publications for Adenomatous Polyposis Coli

About this section

Articles related to Adenomatous Polyposis Coli:

(show top 50)    (show all 293)
idTitleAuthorsYear
1
Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer. (26760960)
2016
2
Characterization of Adenomatous Polyposis Coli Protein Dynamics and Localization at the Centrosome. (27144584)
2016
3
Adenomatous Polyposis Coli Mutation Leads to Myopia Development in Mice. (26495845)
2015
4
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis. (26334567)
2015
5
different Roles for the axin interactions with the SAMP versus the second twenty amino acid repeat of adenomatous polyposis coli. (24722208)
2014
6
Two Chinese pedigrees for adenomatous polyposis coli: new mutations at codon 1309 and predisposition to phenotypic variations. (24664542)
2014
7
Desmoid tumour biology in patients with familial adenomatous polyposis coli. (23334997)
2013
8
Adenomatous polyposis coli gene involvement in ileal enterochromaffin cell neuroendocrine neoplasms. (24139208)
2013
9
Adenomatous polyposis coli (APC) regulates multiple signaling pathways by enhancing glycogen synthase kinase-3 (GSK-3) activity. (22184111)
2012
10
Hypermethylation of adenomatous polyposis coli gene promoter is associated with novel Wnt signaling pathway in gastric adenomas. (22741528)
2012
11
Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis. (22120905)
2012
12
Reversible modification of adenomatous polyposis coli (APC) with K63-linked polyubiquitin regulates the assembly and activity of the I^-catenin destruction complex. (22761442)
2012
13
Amer2 protein interacts with EB1 protein and adenomatous polyposis coli (APC) and controls microtubule stability and cell migration. (22898821)
2012
14
Adenomatous polyposis coli regulates axon arborization and cytoskeleton organization via its N-terminus. (21915313)
2011
15
Novel double-negative feedback loop between adenomatous polyposis coli and Musashi1 in colon epithelia. (21199875)
2011
16
Proteomic identification of overexpressed adenomatous polyposis coli and cyclin B3 during endoderm differentiation from human embryonic stem cells. (21404461)
2011
17
Crystal structure of the armadillo repeat domain of adenomatous polyposis coli which reveals its inherent flexibility. (21871439)
2011
18
A novel frameshift mutation in exon 12 of the adenomatous polyposis coli gene in an Italian family with familial adenomatous polyposis and desmoid tumour. (20589194)
2010
19
Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced colorectal adenoma risk. (20510605)
2010
20
The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15. (19576224)
2009
21
Recruitment of adenomatous polyposis coli and beta-catenin to axin-puncta. (18591934)
2008
22
Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. (18937283)
2008
23
A novel function of adenomatous polyposis coli (APC) in regulating DNA repair. (18662849)
2008
24
Effect of adenomatous polyposis coli(APC) promoter methylation on gene transcription in lung cancer cell lines]. (17562260)
2007
25
Haploinsufficiency of KrA1ppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. (17671182)
2007
26
Impact of adenomatous polyposis coli (APC) tumor supressor gene in human colon cancer cell lines on cell cycle arrest by apigenin. (17620292)
2007
27
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. (16982769)
2006
28
Immunohistochemical detection of beta-catenin and adenomatous polyposis coli in ameloblastomas. (16011608)
2005
29
Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion. (14679305)
2004
30
Cyclooxygenase 2 inhibitors and adenomatous polyposis coli]. (15899631)
2004
31
Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes. (15449054)
2004
32
Novel germline mutations in the adenomatous polyposis coli gene in Polish families with familial adenomatous polyposis. (14729851)
2004
33
Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. (12841871)
2003
34
The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. (11856748)
2002
35
Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. (11696170)
2001
36
Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. (11707392)
2001
37
Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. (10906131)
2000
38
Adenomatous polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and cytoplasm. (11035805)
2000
39
Beta-catenin and adenomatous polyposis coli (APC) mutations in adenomas from hereditary non-polyposis colorectal cancer patients. (10936679)
2000
40
Genotype-phenotype correlations in attenuated adenomatous polyposis coli. (9585611)
1998
41
Absence of somatic alterations of the EB1 gene adenomatous polyposis coli-associated protein in human sporadic colorectal cancers. (9823979)
1998
42
The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli. (9809998)
1998
43
Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. (9041254)
1997
44
Deletion of an amino-terminal sequence beta-catenin in vivo and promotes hyperphosporylation of the adenomatous polyposis coli tumor suppressor protein. (8754807)
1996
45
High resolution genetic map of the adenomatous polyposis coli gene (APC) region. (7604852)
1995
46
Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac. (7723369)
1995
47
Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. (7962323)
1994
48
Purification of recombinant adenomatous polyposis coli polypeptide chains from E. coli extracts by continuous-elution electrophoresis. (8199219)
1993
49
50

Variations for Adenomatous Polyposis Coli

About this section

UniProtKB/Swiss-Prot genetic disease variations for Adenomatous Polyposis Coli:

67 (show all 11)
id Symbol AA change Variation ID SNP ID
1APCp.Ser171IleVAR_005032
2APCp.Arg414CysVAR_005033rs137854567
3APCp.Ser784ThrVAR_005034
4APCp.Glu911GlyVAR_005038
5APCp.Pro1176LeuVAR_005044
6APCp.Thr1313AlaVAR_005051
7APCp.Arg1348TrpVAR_005053
8APCp.Ser2621CysVAR_005056rs72541816
9APCp.Leu2839PheVAR_005057
10APCp.Ser722GlyVAR_009614
11APCp.Ala1184ProVAR_009616

Clinvar genetic disease variations for Adenomatous Polyposis Coli:

5 (show all 74)
id Gene Variation Type Significance SNP ID Assembly Location
1APCNM_000038.5(APC): c.2413C> T (p.Arg805Ter)single nucleotide variantPathogenicrs587779783GRCh38Chr 5, 112838007: 112838007
2APCNM_000038.5(APC): c.3088A> T (p.Lys1030Ter)single nucleotide variantPathogenicrs587779786GRCh38Chr 5, 112838682: 112838682
3APCNM_000038.5(APC): c.4732T> G (p.Cys1578Gly)single nucleotide variantLikely pathogenicrs138367627GRCh37Chr 5, 112176023: 112176023
4APCNM_000038.5(APC): c.5934_5937delAAAC (p.Asn1979Thrfs)deletionPathogenicrs587781330GRCh37Chr 5, 112177225: 112177228
5APCNM_000038.5(APC): c.449A> G (p.Lys150Arg)single nucleotide variantLikely pathogenicrs371085910GRCh37Chr 5, 112111352: 112111352
6APCNM_000038.5(APC): c.2004delC (p.Leu669Terfs)deletionPathogenicrs587782303GRCh37Chr 5, 112173295: 112173295
7APCNM_000038.5(APC): c.426_427delAT (p.Leu143Alafs)deletionPathogenicrs587782557GRCh38Chr 5, 112775632: 112775633
8APCNM_000038.5(APC): c.3286C> T (p.Gln1096Ter)single nucleotide variantPathogenicrs587783029GRCh38Chr 5, 112838880: 112838880
9APCNM_000038.5(APC): c.2107delG (p.Ala703Glnfs)deletionPathogenicrs587783030GRCh38Chr 5, 112837701: 112837701
10APCNM_000038.5(APC): c.4666delA (p.Thr1556Leufs)deletionPathogenicrs587783031GRCh38Chr 5, 112840260: 112840260
11APCNM_000038.5(APC): c.3814delT (p.Ser1272Glnfs)deletionPathogenicrs587783033GRCh38Chr 5, 112839408: 112839408
12APCNM_000038.5(APC): c.1744-2A> Gsingle nucleotide variantPathogenicrs587783035GRCh38Chr 5, 112834949: 112834949
13APCNM_000038.5(APC): c.477delC (p.Tyr159Terfs)deletionPathogenicrs730880250GRCh37Chr 5, 112111380: 112111380
14APCNM_000038.5(APC): c.1312+3_1312+4delATdeletionPathogenicrs730881228GRCh38Chr 5, 112819347: 112819348
15APCNM_000038.5(APC): c.3149delC (p.Ala1050Glufs)deletionPathogenicrs730882135GRCh38Chr 5, 112838743: 112838743
16APCNM_000038.5(APC): c.925G> T (p.Gly309Ter)single nucleotide variantPathogenicrs786204118GRCh37Chr 5, 112151282: 112151282
17APCNM_000038.5(APC): c.3830T> G (p.Leu1277Ter)single nucleotide variantPathogenicrs786204169GRCh38Chr 5, 112839424: 112839424
18APCNM_000038.5(APC): c.4175C> A (p.Ser1392Ter)single nucleotide variantPathogenicrs786204170GRCh38Chr 5, 112839769: 112839769
19APCNM_000038.5(APC): c.1262G> A (p.Trp421Ter)single nucleotide variantPathogenicrs559510809GRCh38Chr 5, 112819294: 112819294
20APCNM_000038.5(APC): c.2563_2564delGA (p.Glu855Thrfs)deletionPathogenicrs794727160GRCh37Chr 5, 112173854: 112173855
21APCNM_000038.5(APC): c.4348C> T (p.Arg1450Ter)single nucleotide variantPathogenicrs121913332GRCh37Chr 5, 112175639: 112175639
22APCNM_000038.5(APC): c.1072C> T (p.Gln358Ter)single nucleotide variantPathogenicrs863224455GRCh38Chr 5, 112819104: 112819104
23APCNM_000038.5(APC): c.1409-?_*(1_?)deldeletionPathogenicGRCh38Chr 5, 112827108: 112844127
24APCNM_000038.5(APC): c.2626C> T (p.Arg876Ter)single nucleotide variantPathogenicrs121913333GRCh38Chr 5, 112838220: 112838220
25APCNM_000038.5(APC): c.3921_3924delAAAA (p.Ile1307Metfs)deletionPathogenicrs863224457GRCh38Chr 5, 112839515: 112839518
26APCNM_000038.5(APC): c.423G> T (p.Arg141Ser)single nucleotide variantPathogenicrs863224458GRCh37Chr 5, 112111326: 112111326
27APCNM_000038.5(APC): c.791delA (p.Gly265Glufs)deletionPathogenicrs863224459GRCh37Chr 5, 112137037: 112137037
28APCNM_000038.5(APC): c.1886dupT (p.Leu629Phefs)duplicationPathogenicrs863224817GRCh37Chr 5, 112170790: 112170790
29APCNM_000038.5(APC): c.453delA (p.Glu152Lysfs)deletionPathogenicrs863224820GRCh37Chr 5, 112111356: 112111356
30APCNM_000038.5(APC): c.1312+3A> Gsingle nucleotide variantLikely pathogenic, Pathogenicrs863225311GRCh38Chr 5, 112819347: 112819347
31APCNM_000038.5(APC): c.423-?_531+?deldeletionPathogenic
32APCNM_000038.5(APC): c.5145delCdeletionPathogenicrs863225363GRCh38Chr 5, 112840739: 112840739
33APCNM_000038.5(APC): c.3404_3405delATdeletionPathogenicrs864622086GRCh37Chr 5, 112174695: 112174696
34APCNM_000038.5(APC): c.3595_3596delAAdeletionPathogenicrs864622106GRCh37Chr 5, 112174886: 112174887
35APCNM_000038.5(APC): c.5826_5829delCAGAdeletionPathogenicrs864622228GRCh38Chr 5, 112841420: 112841423
36APCNM_000038.5(APC): c.730_731delAG (p.Arg244Valfs)deletionPathogenicrs387906228GRCh37Chr 5, 112136976: 112136977
37APCNM_000038.5(APC): c.1369delT (p.Ser457Hisfs)deletionPathogenicrs387906229GRCh37Chr 5, 112157649: 112157649
38APCNM_000038.5(APC): c.1500T> G (p.Tyr500Ter)single nucleotide variantPathogenicrs387906230GRCh37Chr 5, 112162896: 112162896
39APCNM_000038.5(APC): c.904C> T (p.Arg302Ter)single nucleotide variantPathogenicrs137854568GRCh37Chr 5, 112151261: 112151261
40APCNM_000038.5(APC): c.4012C> T (p.Gln1338Ter)single nucleotide variantPathogenicrs121913327GRCh37Chr 5, 112175303: 112175303
41APCNM_000038.5(APC): c.509_512delATAG (p.Asp170Valfs)deletionPathogenicrs387906231GRCh37Chr 5, 112111412: 112111415
42APCNM_000038.5(APC): c.1069dupA (p.Ile357Asnfs)duplicationPathogenicrs387906232GRCh37Chr 5, 112154798: 112154798
43APCNM_000038.5(APC): c.1621C> T (p.Gln541Ter)single nucleotide variantPathogenicrs137854572GRCh37Chr 5, 112163698: 112163698
44APCNM_000038.5(APC): c.1660C> T (p.Arg554Ter)single nucleotide variantPathogenicrs137854573GRCh37Chr 5, 112164586: 112164586
45APCNM_000038.5(APC): c.1690C> T (p.Arg564Ter)single nucleotide variantPathogenicrs137854574GRCh37Chr 5, 112164616: 112164616
46APCNM_000038.5(APC): c.1885_1886insA (p.Leu629Tyrfs)insertionPathogenicrs387906233GRCh37Chr 5, 112170789: 112170790
47APCNM_000038.5(APC): c.2805C> A (p.Tyr935Ter)single nucleotide variantPathogenicrs137854575GRCh37Chr 5, 112174096: 112174096
48APCNM_000038.5(APC): c.470G> A (p.Trp157Ter)single nucleotide variantPathogenicrs137854576GRCh37Chr 5, 112111373: 112111373
49APCNM_000038.5(APC): c.643C> T (p.Gln215Ter)single nucleotide variantPathogenicrs137854577GRCh37Chr 5, 112116598: 112116598
50NC_000005.10: g.112836913_112908314del71402deletionPathogenicGRCh37Chr 5, 112172610: 112244011
51APCNM_000038.5(APC): c.3927_3931delAAAGA (p.Glu1309Aspfs)deletionPathogenicrs121913224GRCh37Chr 5, 112175218: 112175222
52APCNM_000038.5(APC): c.5942delA (p.Asn1981Ilefs)deletionPathogenicrs397509433GRCh37Chr 5, 112177233: 112177233
53APCNM_000038.5(APC): c.5582_5585delCTTT (p.Ser1861Terfs)deletionPathogenicrs587776520GRCh38Chr 5, 112841176: 112841179
54APCNM_000038.5(APC): c.3920T> A (p.Ile1307Lys)single nucleotide variantPathogenic, risk factorrs1801155GRCh37Chr 5, 112175211: 112175211
55APCNM_000038.5(APC): c.1495C> T (p.Arg499Ter)single nucleotide variantPathogenicrs137854580GRCh37Chr 5, 112162891: 112162891
56APCAPC, TYR486TERsingle nucleotide variantPathogenic
57APCNM_000038.5(APC): c.1311_1312+1delAAGdeletionPathogenicrs397514030GRCh37Chr 5, 112155040: 112155042
58APCNM_000038.5(APC): c.1098_1099delCT (p.Ser367Cysfs)deletionPathogenicrs387906237GRCh37Chr 5, 112154827: 112154828
59APCNM_000038.5(APC): c.1192_1193delAA (p.Lys398Glufs)deletionPathogenicrs387906238GRCh37Chr 5, 112154921: 112154922
60APCNM_000038.5(APC): c.937_938delGA (p.Glu313Asnfs)deletionPathogenicrs387906239GRCh37Chr 5, 112154666: 112154667
61APCAPC deletiondeletionPathogenicGRCh38Chr 5, 112707504: 112846240
62APCNM_000038.5(APC): c.423-1G> Asingle nucleotide variantPathogenicrs397514031GRCh37Chr 5, 112111325: 112111325
63APCAPC, 11-BP INS, NT1060insertionPathogenic
64APCNG_008481.4: g.(?_150033)_(158719_?)deldeletionPathogenicGRCh38Chr 5, 112837553: 112846239
65APCAPC, 5-BP DEL, NT3221deletionPathogenic
66APCNM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs)deletionPathogenicrs587779352GRCh37Chr 5, 112174474: 112174478
67APCNM_000038.5(APC): c.3202_3205delTCAA (p.Ser1068Glyfs)deletionPathogenicrs587779353GRCh37Chr 5, 112174493: 112174496
68APCNM_000038.5(APC): c.1659G> A (p.Trp553Ter)single nucleotide variantPathogenicrs398123116GRCh37Chr 5, 112164585: 112164585
69APCNM_000038.5(APC): c.2365C> T (p.Gln789Ter)single nucleotide variantPathogenicrs398123117GRCh37Chr 5, 112173656: 112173656
70APCNM_000038.5(APC): c.2547_2550delTAGA (p.Asp849Glufs)deletionPathogenicrs398123118GRCh37Chr 5, 112173838: 112173841
71APCNM_000038.5(APC): c.2731G> T (p.Glu911Ter)single nucleotide variantPathogenicrs398123119GRCh37Chr 5, 112174022: 112174022
72APCNM_000038.5(APC): c.2805delC (p.Tyr935Terfs)deletionPathogenicrs398123120GRCh37Chr 5, 112174096: 112174096
73APCNM_000038.5(APC): c.3982C> T (p.Gln1328Ter)single nucleotide variantPathogenicrs398123121GRCh37Chr 5, 112175273: 112175273
74APCNM_000038.5(APC): c.4473dupT (p.Ala1492Cysfs)duplicationPathogenicrs398123122GRCh38Chr 5, 112840067: 112840067

Cosmic variations for Adenomatous Polyposis Coli:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM516KRASlarge intestine,colon,other,dysplasia4
2COSM521KRASlarge intestine,colon,other,dysplasia4
3COSM528KRASlarge intestine,colon,other,dysplasia4
4COSM532KRASlarge intestine,colon,other,dysplasia4
5COSM11552TP53large intestine,colon,other,dysplasia4
6COSM28747IDH1large intestine,colon,other,dysplasia4
7COSM11354TP53large intestine,rectum,other,dysplasia3
8COSM14143SMAD4large intestine,rectum,other,dysplasia3

Expression for genes affiliated with Adenomatous Polyposis Coli

About this section
Search GEO for disease gene expression data for Adenomatous Polyposis Coli.

Pathways for genes affiliated with Adenomatous Polyposis Coli

About this section

Pathways related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 37)
idSuper pathwaysScoreTop Affiliating Genes
19.8AXIN1, GSK3B
29.7CTNNB1, IQGAP1
39.7APC, GSK3B, MAPRE1
49.6AXIN1, CTNNB1, MAPRE1
59.5APC, CTNNB1, TCF7L2
69.4CTNNB1, GSK3B, TCF7L2
7
Show member pathways
9.4CTNNB1, GSK3B, TCF7L2
8
Show member pathways
9.2AXIN1, AXIN2, CTNNB1, GSK3B
99.2CTNNB1, IQGAP1, TCF7L2
10
Show member pathways
9.2APC, CTNNB1, GSK3B, IQGAP1
119.1APC, AXIN2, CTNNB1, TCF7L2
12
Show member pathways
9.1CTNNB1, GSK3B, WNT1
13
Show member pathways
8.9CTNNB1, GSK3B, IQGAP1, TCF7L2
148.8CTNNB1, IQGAP1, MAPRE1, MAPRE2, MAPRE3
158.8APC, AXIN1, CTNNB1, GSK3B, TCF7L2
168.6APC, APC2, CTNNB1, GSK3B, WNT1
17
Show member pathways
8.6AMER1, APC, AXIN1, CTNNB1, GSK3B, TCF7L2
18
Show member pathways
8.6CTNNB1, GSK3B, TCF7L2, WNT1
198.5APC, AXIN1, CTNNB1, GSK3B, WNT1
208.5APC, AXIN1, CTNNB1, GSK3B, WNT1
218.5APC, AXIN1, CTNNB1, GSK3B, WNT1
228.5APC, AXIN1, CTNNB1, GSK3B, WNT1
23
Show member pathways
8.2APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
24
Show member pathways
8.0APC, AXIN1, CTNNB1, GSK3B, TCF7L2, WNT1
258.0APC, AXIN1, CTNNB1, GSK3B, TCF7L2, WNT1
268.0APC, AXIN2, CTNNB1, GSK3B, TCF7L2, WNT1
27
Show member pathways
8.0AMER1, APC, AXIN1, CTNNB1, FEN1, GSK3B
287.9APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
297.8AXIN1, AXIN2, CTNNB1, GSK3B, TCF7L2, WNT1
30
Show member pathways
7.6APC, AXIN1, AXIN2, CTNNB1, GSK3B, TCF7L2
31
Show member pathways
7.6APC, AXIN1, AXIN2, CTNNB1, GSK3B, TCF7L2
32
Show member pathways
7.4APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
33
Show member pathways
7.4APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
347.4APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
357.4APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
36
Show member pathways
7.4AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
37
Show member pathways
7.4AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B

GO Terms for genes affiliated with Adenomatous Polyposis Coli

About this section

Cellular components related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1lateral plasma membraneGO:001632810.0APC, IQGAP1
2cytoplasmic microtubuleGO:00058819.8AXIN1, AXIN2
3microtubule plus-endGO:00353719.7MAPRE1, MAPRE2, MAPRE3
4cell cortexGO:00059389.2APC, AXIN1, AXIN2, CTNNB1
5protein complexGO:00432349.2APC, CTNNB1, GSK3B, IQGAP1

Biological processes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1cellular response to lithium ionGO:007128510.4CTNNB1, GSK3B
2regulation of centromeric sister chromatid cohesionGO:007060210.4AXIN2, CTNNB1
3epithelial to mesenchymal transitionGO:000183710.3CTNNB1, GSK3B
4cell fate specificationGO:000170810.2APC, APC2, CTNNB1
5maintenance of DNA repeat elementsGO:004357010.2AXIN2, TCF7L2
6cellular response to fibroblast growth factor stimulusGO:004434410.2CTNNB1, IQGAP1
7positive regulation of peptidyl-threonine phosphorylationGO:001080010.2AXIN1, GSK3B
8positive regulation of insulin secretionGO:003202410.0GLUL, TCF7L2
9negative regulation of catenin import into nucleusGO:003541410.0APC2, AXIN2
10beta-catenin destruction complex assemblyGO:190488510.0APC, AXIN1, GSK3B
11embryonic brain developmentGO:199040310.0CTNNB1, WNT1
12midbrain developmentGO:003090110.0CTNNB1, WNT1
13T cell differentiation in thymusGO:00330779.9CTNNB1, WNT1
14dopaminergic neuron differentiationGO:00715429.9CTNNB1, WNT1
15myotube differentiationGO:00149029.9GSK3B, WNT1
16proteasome-mediated ubiquitin-dependent protein catabolic processGO:00431619.8AMER1, APC, AXIN1, CTNNB1
17forebrain anterior/posterior pattern specificationGO:00217979.7AXIN1, WNT1
18beta-catenin-TCF complex assemblyGO:19048379.7AXIN2, CTNNB1, TCF7L2
19myoblast fusionGO:00075209.5GSK3B, WNT1
20negative regulation of canonical Wnt signaling pathwayGO:00900909.4AMER1, APC2, AXIN2, GSK3B
21positive regulation of GTPase activityGO:00435478.9AXIN1, AXIN2, GSK3B, SPATA13
22beta-catenin destruction complex disassemblyGO:19048868.6AMER1, APC, AXIN1, CTNNB1, GSK3B, WNT1
23canonical Wnt signaling pathwayGO:00600708.5AXIN1, CTNNB1, GSK3B, TCF7L2, WNT1
24positive regulation of canonical Wnt signaling pathwayGO:00902638.4AMER1, AXIN1, AXIN2, GSK3B, WNT1
25Wnt signaling pathwayGO:00160558.1AMER1, APC2, AXIN1, AXIN2, GSK3B, WNT1

Molecular functions related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1gamma-catenin bindingGO:00452959.5APC, APC2, TCF7L2
2beta-catenin bindingGO:00080139.2AMER1, AXIN1, AXIN2, GSK3B

Sources for Adenomatous Polyposis Coli

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet